EP1004674B1 - Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine - Google Patents

Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine Download PDF

Info

Publication number
EP1004674B1
EP1004674B1 EP98923100A EP98923100A EP1004674B1 EP 1004674 B1 EP1004674 B1 EP 1004674B1 EP 98923100 A EP98923100 A EP 98923100A EP 98923100 A EP98923100 A EP 98923100A EP 1004674 B1 EP1004674 B1 EP 1004674B1
Authority
EP
European Patent Office
Prior art keywords
protein
adamts
human adamts
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98923100A
Other languages
German (de)
English (en)
Other versions
EP1004674A4 (fr
EP1004674A1 (fr
Inventor
Kunitaka Hirose
Eiji Inoguchi
Michinori Hakozaki
Keiko Ishioka
Yukako Ishida
Kouji Matsushima
Koji Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Publication of EP1004674A1 publication Critical patent/EP1004674A1/fr
Publication of EP1004674A4 publication Critical patent/EP1004674A4/fr
Application granted granted Critical
Publication of EP1004674B1 publication Critical patent/EP1004674B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a human ADAMTS-1 protein, a gene encoding the same, a pharmaceutical composition, and a method for immunologically analyzing the human ADAMTS-1 protein.
  • a mouse ADAMTS ( A d isintegrin a nd m etalloproteinase with t hrombo s pondin motifs)-1 gene has been cloned as a cDNA from a mouse colon cancer cell which induces cancer cachexia when transplanted to a mouse.
  • the mouse ADAMTS-1 protein encoded by the gene is a unique protein containing a matrix metalloproteinase domain, a disintegrin domain, and three thrombospondin domains [J. Biol. Chem., 272 , 556-562 (1997)].
  • the physiological functions of the mouse ADAMTS-1 protein has not been reported, but there have been reports of each individual functional domain contained therein.
  • a snake venom disintegrin belongs to a family of proteins which are rich in cystein, and exhibit an anticoagulant activity [Semin. Hematol., 31 , 289-300 (1994)].
  • an ADAM A d isintegrin a nd metalloproteinase family is known as a protein family containing a matrix metalloproteinase domain and a disintegrin domain [Nature, 377 , 652-656 (1995); Nature Genet., 5 , 151-157 (1993); Nature, 356 , 248-252 (1992)].
  • ADAM family proteins are fertilin, epidermal apical protein, cyritestin, MDC (metalloprotease-like, disintegrin-like and cystein-rich protein), meltrin, MS2, and metargidin [Nature, 377 , 652-656 (1995); Nature Genet.
  • the mouse ADAMTS-1 protein contains a matrix metalloproteinase domain and a disintegrin domain, and therefore belongs to the ADAM family. However, the mouse ADAMTS-1 protein is different from other known ADAM family proteins in that it further contains thrombospondin domains.
  • the ADAM family proteins have various kinds of activities such as the involvement of bone or muscle metabolism, suppression of cancer growth, or fertilization, and the thrombospondin exhibits an action to inhibit vascularization and suppresses cancer. Therefore, it is expected that the mouse ADAMTS-1 protein will exhibit unique physiological functions.
  • the inventors of the present invention attempted to isolate the corresponding human ADAMTS-1 protein. Accordingly, the present inventors designed and prepared various probes on the basis of the base sequence of the known mouse ADAMTS-1 gene, and carried out plaque hybridizations with a human kidney cDNA library so as to obtain a human ADAMTS-1 gene, but a desired gene was not obtained. Then, the present inventors designed and prepared various primers on the basis of the base sequence of the known mouse ADAMTS-1 gene, and carried out PCRs, using the human kidney cDNA library as templates under ordinary conditions, so as to obtain the desired gene, but did not succeed.
  • the present inventors carried out a PCR of the human kidney cDNA library, using the same primers, but under conditions milder than those ordinarily used, more particularly, an annealing temperature is set lower than an ordinary temperature, and the inventors successfully obtained a novel human ADAMTS-1 gene.
  • the resulting gene was then, expressed in E. coli, and the biological activities of the recombinant human ADAMTS-1 protein were examined.
  • the novel human ADAMTS-1 protein can decrease the numbers of leukocytes and platelets, and at the same time, increase the number of erythrocytes.
  • the present invention relates to a protein characterized by containing an amino acid sequence of SEQ ID NO: 1:
  • the present invention relates to the variation of proteins which are equivalent to the protein containing the amino acid sequence of SEQ ID NO: 1.
  • the present invention relates to a protein characterized by containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, except for a mouse ADAMTS-1 protein.
  • the present invention relates to a gene characterized by encoding the above novel proteins.
  • the present invention relates to a vector characterized by containing the above gene.
  • the present invention relates to a transformant characterized by being transformed by the above vector.
  • the present invention relates to a pharmaceutical composition characterized by comprising (1) the protein containing the amino acid sequence of SEQ ID NO: 1, (2) the variation functionally equivalent to the protein containing the amino acid sequence of SEQ ID NO: 1, or (3) the protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain.
  • the present invention relates to an immunologically reactive substance (such as a polyclonal antibody or a monoclonal antibody, or an antibody fragment thereof, or an antiserum) characterized by nature of being capable of specifically reacting with the novel proteins.
  • an immunologically reactive substance such as a polyclonal antibody or a monoclonal antibody, or an antibody fragment thereof, or an antiserum
  • the present invention relates to a method for immunologically analyzing the human ADAMTS-1 protein, characterized in that a sample is brought into contact with the immunologically reactive substance, and a complex of the human ADAMTS-1 protein and the immunologically reactive substance is detected.
  • the present invention relates to a method for analyzing an mRNA of the human ADAMTS-1 protein, characterized in that a sample is brought into contact with a polynucleotide containing a base sequence complementary to that of the mRNA of the human ADAMTS-1 protein consisting of the amino acid sequence of SEQ ID NO: 1, and a complex of the mRNA of the human ADAMTS-1 protein and the gene polynucleotide is detected.
  • the present invention relates to a method for extracorporeally detecting an immunological state, characterized by analyzing the human ADAMTS-1 protein or the mRNA thereof.
  • the present invention relates to an agent for analyzing an immunological state, characterized by containing the immunologically reactive substance capable of immunologically reacting the human ADAMTS-1 protein or the polynucleotide containing the base sequence complementary to that of the mRNA of the human ADAMTS-1 protein.
  • the human ADAMTS-1 protein of the present invention is a novel protein consisting of 727 amino acid residues; that is, consisting of the amino acid sequence of SEQ ID NO: 1.
  • the human ADAMTS-1 protein of the present invention contains a matrix metalloproteinase (hereinafter sometimes referred to as "MMP") domain consisting of the 12th to 230th amino acid residues counting from the N-terminal amino acid residue, methionine; a disintegrin (hereinafter sometimes referred to as "DI”) domain consisting of the 235th to 305th amino acid residues; and three thrombospondin (hereinafter sometimes referred to as "TSP”) domains consisting of the 322nd to 372nd, 618th to 664th, and 672nd to 727th amino acid residues.
  • MMP matrix metalloproteinase
  • DI disintegrin
  • TSP three thrombospondin
  • the human ADAMTS-1 protein contains many arginines and lysines, which are basic amino acids, in a C-terminal region. Therefore, it is believed that the human ADAMTS-1 protein interacts with sulfated polysaccharide molecules, such as heparin or heparan sulfate, in blood.
  • the novel protein according to the present invention includes the protein containing the amino acid sequence of SEQ ID NO: 1; and a variation functionally equivalent to the protein containing the amino acid sequence of SEQ ID NO: 1 (hereinafter sometimes referred to as a "human ADAMTS-1 protein variation").
  • human ADAMTS-1 protein variation as used herein means a protein having an amino acid sequence wherein one or more (particularly one or several) amino acids are deleted in, changed in, or inserted to the amino acid sequence of the human ADAMTS-1 protein, that is, the amino acid sequence of SEQ ID NO: 1, and exhibiting activities of the human ADAMTS-1 protein.
  • a preferable human ADAMTS-1 protein variation has a 92% or more homology in the amino acid sequence with the human ADAMTS-1 protein.
  • the human ADAMTS-1 protein variation includes a fragment which is a part of the protein containing the amino acid sequence of SEQ ID NO: 1 and exhibits the activities of the human ADAMTS-1 protein; and a fragment which is a part of another human ADAMTS-1 protein variation and exhibits the activities of the human ADAMTS-1 protein.
  • human ADAMTS-1 activity means an activity to decrease the numbers of leukocytes and platelets, and at the same time, increase the number of erythrocytes.
  • novel protein of the present invention includes a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain (hereinafter sometimes referred to as an "ADAMTS protein").
  • ADAMTS protein a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain
  • mouse ADAMTS-1 protein is not included in the novel protein of the present invention.
  • matrix metalloproteinase domain means a domain containing an amino acid sequence having a 50% or more (preferably 95% or more) homology with the amino acid sequence of the matrix metalloproteinase domain in the human ADAMTS-1 protein, i.e., the amino acid sequence of the 12th to 230th amino acids in the amino acid sequence of SEQ ID NO: 1.
  • disintegrin domain means a domain containing an amino acid sequence having a 50% or more (preferably 93% or more) homology with the amino acid sequence of the disintegrin domain in the human ADAMTS-1 protein, i.e., the amino acid sequence of the 235th to 305th amino acids in the amino acid sequence of SEQ ID NO: 1.
  • thrombospondin domain means a domain containing an amino acid sequence having a 50% or more homology with at least one of the amino acid sequences of three disintegrin domains in the human ADAMTS-1 protein, that is,
  • the number of each of the matrix metalloproteinase domain, the disintegrin domain, and the thrombospondin domain, and the sequential order thereof, are not particularly limited, so long as at least one matrix metalloproteinase domain, at least one disintegrin domain, and at least one thrombospondin domain are contained at the same time in the ADAMTS protein.
  • a preferred ADAMTS protein contains a matrix metalloproteinase domain, a disintegrin domain and three thrombospondin domains.
  • the sequential order of the domains from the N-terminus to the C-terminus preferably starts from the matrix metalloproteinase domain, followed by the disintegrin domain, and then the thrombospondin domain.
  • the sequential order of the domains from the N-terminus to the C-terminus preferably starts from the matrix metalloproteinase domain, followed by the disintegrin domain, and then the first TSP domain, the second TSP domain and the third TSP domain.
  • ADAMTS protein of the present invention it is preferable that
  • ADAMTS protein containing three thrombospondin domains it is preferable that
  • the protein of the present invention may be prepared by various known processes.
  • the protein of the present invention may be prepared using a known genetic engineering technique and the gene of the present invention.
  • the protein of the present invention may be purified from a naturally occurring source, using a known protein chemical technique.
  • the gene of the present invention includes a gene encoding the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein; a gene encoding the human ADAMTS-1 protein variation; and a gene encoding the ADAMTS protein (except the mouse ADAMTS-1 protein).
  • the present gene may be DNA or RNA.
  • the gene encoding the human ADAMTS-1 protein may be, for example, a gene consisting of the base sequence of SEQ ID NO: 2:
  • the gene of the present invention such as the gene consisting of the base sequence of SEQ ID NO: 2, may be obtained, for example, by the following method, which was used by the present inventors when the present gene was obtained for the first time.
  • DNA fragments may be obtained by carrying out a PCR under a condition milder than that of an ordinary PCR, i.e., at an annealing temperature lower than a usual annealing temperature, using a human kidney cDNA library as templates. Base sequences of the resulting DNA fragments are determined, and compared with the base sequence of the mouse ADAMTS-1 gene, to thereby identify the resulting DNA fragments as the desired genes.
  • a full-length human ADAMTS-1 gene or a partial base sequence of the human ADAMTS-1 gene may be obtained.
  • the remaining base sequence of the gene may be obtained by a RACE ( R apid a mplification of c DNA e nds) method [Proc Natl. Acad. Sci. USA, 85 , 8998-9002 (1988)], and partial base sequences may be ligated by genetic-engineering to obtain the full-length base sequence.
  • RACE R apid a mplification of c DNA e nds
  • the present inventors used primers designed on the basis of the base sequence of the mouse ADAMTS-1 gene to carry out a PCR at a usual temperature, but a desired DNA fragment could not be obtained.
  • the present inventors used the same primers and carried out a PCR under a condition milder than that of an ordinary PCR, i.e., an annealing temperature was set lower than a usual annealing temperature, whereby the desired DNA fragment was able to be obtained.
  • the comparison of the base sequence of the resulting human ADAMTS-1 gene with the base sequences of the primers used revealed an insufficient homology.
  • the base sequence of the human ADAMTS-1 gene has been determined according to the present invention. Therefore, the base sequence of the human ADAMTS-1 gene may be used to design primers for a PCR or probes for plaque hybridization. Such primers or probes may be used to obtain the gene of the present invention by a known method to obtain a gene, such as a PCR under ordinary conditions or plaque hybridization, instead of the method used by the present inventors to obtain the present gene for the first time.
  • the present inventors attempted to obtain an unknown human ADAMTS-1 gene from the human kidney cDNA library by plaque hybridization, using probes designed on the basis of the base sequence of the known mouse ADAMTS-1 gene, but a desired gene was not obtained.
  • One of the reasons of this failure was an insufficient homology of the probes used.
  • the present inventors have carried out northern hybridization to analyze the mRNA of the human ADAMTS-1 protein, and confirmed that the failure must also have occurred because mRNA is expressed in a very small amount, and thus a very small number of the human ADAMTS-1 genes are copied in a cDNA library.
  • the gene of the present invention may be obtained by plaque hybridization, using probes designed on the basis of the base sequence of the human ADAMTS-1 gene.
  • the resulting gene of the present invention may be expressed in, for example, a eucaryotic or procaryotic host to produce the protein of the present invention.
  • a vector which may be used preferably contains genetic information necessary for replication in a host cell, can be independently replicated, is easily isolated and purified from a host cell, and contains a detectable marker.
  • An expression vector containing the DNA of the present invention may be constructed in accordance with a host cell from various commercially available vectors. A method for introducing the DNA into the vector is well known.
  • E. coli strains such as XL1-Blue, HB101, JM109, DH5 ⁇ , AG-1, K12 strain 294 (ATCC 31446), B, ⁇ 1776 (ATCC 31537), C600, or W3110 (F-, ⁇ -, prototrophic; ATCC 27375).
  • Bacillus strains such as Bacillus subtibis, enteric bacteria, such as Salmonella typhimurium or Serratia marcescens, or Pseudomonas strains may be used.
  • an expression plasmid which may be used as a vector contains a promoter, an SD base sequence, and a base sequence necessary for initiating a protein synthesis, i.e., ATG, upstream of the gene of the present invention so as to express the gene.
  • a vector for E. coli strains pUC19, pBR322, or pBR327 are generally and widely used.
  • a promoter for example, triptophan promoter, P L promoter, lac promoter, tac promoter, trc promoter, lpp promoter, or ⁇ -lactamase promoter may be used.
  • the marker gene are an ampicillin resistance gene or tetracycline resistance gene.
  • a yeast As a eucaryotic host, a yeast is generally and widely used. Of the yeasts, a Saccharomyces yeast can be advantageously used. As an expression vector for the eucaryotic host such as a yeast, for example, YRp7 may be used
  • a promoter of the expression vector for a yeast expression for example, alcohol dehydrogenase (ADH), GAL10, 3-phosphoglycerate kinase, enolase, glyceraldehyde-3-phosphate dehydrogenase, or hexokinase may be used.
  • ADH alcohol dehydrogenase
  • GAL10 3-phosphoglycerate kinase
  • enolase glyceraldehyde-3-phosphate dehydrogenase
  • hexokinase hexokinase
  • a stop codon, or other DNA sequences used to control a transcription or translation in a yeast cell usual known DNA sequences suitable to the yeast cell may be used.
  • a culture cell host of a higher animal there may be mentioned, for example, a rhesus renal cell, a mosquito larva cell, an African Green Monkey kidney cell (COS-7 or COS-1), a murine fetal fibroblast, a Chinese hamster ovary cell or a dihydrofolate reductase-defective strain thereof, a human cervical epitheliocyte, a human fetal kidney cell, a moth ovary cell, a human myeloma cell, or a murine fibroblast cell.
  • COS-7 or COS-1 African Green Monkey kidney cell
  • a murine fetal fibroblast a Chinese hamster ovary cell or a dihydrofolate reductase-defective strain thereof
  • a human cervical epitheliocyte a human fetal kidney cell, a moth ovary cell, a human myeloma cell, or a murine fibroblast cell.
  • the vector generally contains functional sequences to express the DNA of the present invention in a host cell, for example, a replication origin, a promoter, which should be upstream of the DNA of the present invention, a ribosome binding site, a polyadenylated site, and/or a transcription termination sequence.
  • a preferable promoter is, for example, an adenovirus 2 main late promoter, SV40 early promoter, SV40 late promoter, or a promoter from cytomegalovirus, Rous sarcoma virus, or an eucaryote gene, such as estrogen inducible chick egg albumin gene, interferon gene, glucocorticoid inducible throsine aminotransferase gene, thymidine kinase gene, main early and late adenovirus gene, phosphoglycerate kinase gene, or ⁇ factor gene.
  • an adenovirus 2 main late promoter such as estrogen inducible chick egg albumin gene, interferon gene, glucocorticoid inducible throsine aminotransferase gene, thymidine kinase gene, main early and late adenovirus gene, phosphoglycerate kinase gene, or ⁇ factor gene.
  • a replication origin from adenovirus, SV40, bovine papilloma virus (BPV), vesicular stomatitis virus (VSV), or a derivative vector thereof may be used as the replication origin.
  • a neomycin resistance gene, a methotrexate resistant dihydrofolate reductase (DHR) gene, or a blasticidin S resistance gene may be used as the marker gene.
  • a gene transfer to the insect cell can be carried out by co-infecting the insect cell with a virus DNA and a transfer vector containing a desired gene to be incorporated.
  • virus DNA for example, a Bombyx mori nuclear polyhedrosis virus, or Autographica californica multiple nuclear polyhedrosis virus may be used.
  • transfer vector containing the desired gene to be inserted for example, a polyhedrin promoter or p10 promoter vector may be used. The desired gene can be inserted downstream of the promoters.
  • the transfer vector can be replicated in E. coli, but cannot be replicated in an insect cell. Therefore, it is preferable to replicate many vectors in E. coli, and then express them in the insect cell. According to this process, a larger amount of expressed substances can be recovered in comparison with an animal cell.
  • the resulting expression plasmid may be transfected into an appropriate host cell, for example, a microorganism cell, such as E. coli yeast, or an animal cell, to produce the transformant of the present invention.
  • the method for transfecting the DNA may be, for example, a method of utilizing a competent cell treated with calcium chloride, a protoplast method, a calcium phosphate transfection method, or an electroporation method.
  • the pharmaceutical composition of the present invention comprises (1) the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, (2) the human ADAMTS-1 protein variation, or (3) the ADAMTS protein, as an active ingredient.
  • the active ingredient may be the mouse ADAMTS-1 protein.
  • the proteins which may be used as the active ingredient of the pharmaceutical composition in the present invention have activities to influence hematopoietic functions, for example, activities to decrease the number of leukocytes and platelets, and at the same time, increase the number of erythrocytes, when administered into a blood vessel.
  • the pharmaceutical composition according to the present invention i.e., the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein, alone or preferably together with a pharmaceutically or veterinarily acceptable ordinary carrier, to an animal, preferably a mammal, particularly humans.
  • the formulation is not particularly limited to, but may be, for example, oral medicines, such as powders, fine subtilaes, granules, tablets, capsules, suspensions, emulsions, syrups, extracts or pills, or parenteral medicines, such as injections, liquids for external use, ointments, suppositories, creams for topical application, or eye lotions.
  • oral medicines such as powders, fine subtilaes, granules, tablets, capsules, suspensions, emulsions, syrups, extracts or pills
  • parenteral medicines such as injections, liquids for external use, ointments, suppositories, creams for topical application, or eye lotions.
  • the oral medicines may be prepared by an ordinary method using, for example, fillers, binders, disintegrating agents, surfactants, lubricants, flowability-enhancers, diluting agents, preservatives, coloring agents, perfumes, tasting agents, stabilizers, humectants, antiseptics, antioxidants, such as gelatin, sodium alginate, starch, corn starch, saccharose, lactose, glucose, mannitol, carboxylmethylcellulose, dextrin, polyvinyl pyrrolidone, crystalline cellulose, soybean lecithin, sucrose, fatty acid esters (such as glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, or propyleneglycol fatty acid ester), talc, magnesium stearate, polyethylene glycol, magnesium silicate, silicic anhydride, or synthetic aluminum silicate.
  • fillers for example, fillers, binders, disintegrating agents, surfactants
  • parenteral administration for example, an injection such as a subcutaneous or intravenous injection, or the per rectum administration may be used.
  • an injection is preferably used.
  • water-soluble solvents such as physiological saline or Ringer's solution
  • water-insoluble solvents such as plant oil or fatty acid ester
  • agents for rendering isotonic such as glucose or sodium chloride
  • solubilizing agents stabilizing agents
  • antiseptics suspending agents
  • emulsifying agents may be optionally used, in addition to the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein.
  • the pharmaceutical composition may be administered in the form of a sustained release preparation using sustained release polymers.
  • the pharmaceutical composition of the present invention may be incorporated to a pellet made of ethylenevinyl acetate polymers, and the pellet may be surgically implanted in a tissue to be treated.
  • the pharmaceutical composition of the present invention may contain the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein in an amount, but not particularly limited to, of 0.0001 to 99% by weight, preferably 0.01 to 80% by weight, more preferably 0.01 to 50% by weight.
  • the dose is not particularly limited, but varies with the kind of disease, the age, sex, body weight, or symptoms of the subject, a method of administration, or the like.
  • the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein may be orally or parenterally administered at a dosage of about 0.0001 ⁇ g/kg to 10,000 ⁇ g/kg, preferably 0.001 ⁇ g/kg to 1,000 ⁇ g/kg, more preferably 0.01 ⁇ g/kg to 100 ⁇ g/kg a day for an adult, usually once or divided into up to four dosages.
  • the pharmaceutical composition of the present invention may be used not only for the pharmaceutical application but also for various applications. That is, the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein may be administered in the form of functional food or health food, together with a conventional food additive, or directly added to food as a food additive.
  • the pharmaceutical composition of the present invention contains the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein, and thus is useful as, for example, an agent for reducing leukocytes, an agent for reducing platelets, or an agent for increasing erythrocytes.
  • the human ADAMTS-1 protein of the present invention would be effective in the treatment of various inflammatory diseases, such as rheumatic arthritis, psoriasis, asthma, hepatitis, Kawasaki disease, gout, adult respiratory distress syndrome (ARDS), Crohn's disease, ulcerative colitis, sepsis, or nephritis. Further, the human ADAMTS-1 protein of the present invention exhibits a function to decrease the number of leukocytes and platelets, and thus would be effective in a treatment of true hypervolemia.
  • the human ADAMTS-1 protein of the present invention exhibits a function to decrease the number of platelets. Therefore, it is believed that the human ADAMTS-1 protein of the present invention would exhibit an anti-thrombotic action, and would be effective in the treatment of cardiac infarction, cerebral inferction, or multi-organ failure.
  • the human ADAMTS-1 protein of the present invention exhibits a function to significantly increase the number of erythrocytes, and would be effective in a treatment of anemia, as erythropoietin.
  • LPS lipopolysaccharide
  • an immunologically stimulating substance is administered to a mouse (for example, a 10 ⁇ g/mouse)
  • an expression of the mouse ADAMTS-1 gene is superinduced in a heart and a kidney (J. Biol. Chem., 272 , 556-562 (1997)]. Therefore, the mouse ADAMTS-1 protein would possibly exhibit a protective function for a heart and a kidney, upon a lethally acute inflammation such as an endotoxin shock.
  • Thrombospondin is known as a factor for inhibiting vascularization, i.e., specifically inhibiting a growth of endothelial cells [J. Cell. Biol., 111 , 765-772 (1990)]. Further, it was reported that the proliferation and metastasis of cancer cells can be inhibited by the induction of TSP in cancer cells [J. Cell. Biol., 111 , 765-772 (1990)]. Therefore, the human ADAMTS-1 protein would probably show a function for inhibiting a cancer or metastasis. Further, a recent report had stated that TSP or disintegrin is involved in a bone formation [Biochem. Biophy. Res. Commun., 213 , 1017-1025 (1995)]. Therefore, the human ADAMTS-1 protein could be applicable to the treatment of a metabolic bone disease, such as osteoporosis.
  • a metabolic bone disease such as osteoporosis.
  • the immunologically reactive substance of the present invention specifically reacts the protein containing the amino acid sequence of SEQ ID NO: 1, particularly the human ADAMTS-1 protein, the human ADAMTS-1 protein variation, or the ADAMTS protein.
  • the immunologically reactive substance of the present invention includes, for example, an antibody (a monoclonal antibody or a polyclonal antibody), fragments of the antibody, such as, Fab, Fab', F(ab') 2 , or Fv, and an antiserum.
  • the immunologically reactive substance of the present invention specifically reacts the human ADAMTS-1 protein, and therefore, the immunologically reactive substance of the present invention specifically reacts the human ADAMTS-1 protein, and therefore, is useful for analyzing the human ADAMTS-1 protein by immunological ways.
  • the monoclonal antibody of the present invention may be prepared by a known method, for example, the following method.
  • a physiological salt solution containing an antigen is mixed with an equal volume of complete Freund's adjuvant or incomplete adjuvant, or an equivalent thereof, such as Hunter's TiterMaxTM (Funakoshi; Cat. No. YT001-00, Tokyo, Japan), until emulsified.
  • the resulting emulsion is administered subcutaneously, intraperitoneally, intravenously, intramuscularly, or intradermally to a mammal, for example, a mouse, rat, rabbit, or hamster, more particularly, a mouse, such as a BALB/c mouse, selected in view of a congeniality to a conventional myeloma cell (a first immunization).
  • the resulting spleen cells are used for a cell fusion.
  • the other parent cells used for the cell fusion that is, the myeloma cells, may be known cell lines, such as, P3X63-Ag8(X63) [Nature, 256 , 495-497 (1975)], P3X63-Ag8U1 (P3U1) [Current Topics in Microbiology and Immunology, 81 , 1-7 (1978)], or P3X63Ag8.653 (ATCC deposition No. CRL-1580).
  • the cell fusion may be carried out by ususal methods, for example, the method of Milstein et. al. [Methods in Enzymology, 73 , 3-47 (1981)].
  • the resulting hybridomas are administered to mammals (for example, mice), and desired monoclonal antibodies are separated and purified from ascites of the mammals.
  • the separation and purification method used may be a known method, such as a dialysis ion exchange chromatography using an ammonium sulfate; an affinity column chromatography using a protein A or protein G binding polysaccharides carrier or an anti-mouse immunoglobrin antibody binding polysaccharides carrier; dialysis, or lyophilization.
  • the polyclonal antibody of the present invention may be prepared by a known method, as indicated below. That is, a physiological salt solution containing an antigen is mixed with an equal volume of complete Freund's adjuvant or incomplete adjuvant, or an equivalent thereof, such as Hunter's TiterMaxTM (Funakoshi; Cat. No. YT001-00, Tokyo, Japan), until emulsified. The resulting emulsion is administered subcutaneously, intraperitoneally, or intramuscularly to a mammal, for example, a rabbit, or goat (a first immunization). Then, the same procedure is repeated at intervals of two to four weeks for several immunizations. One or two weeks after a final immunization, blood is taken from a carotid artery or a heart of the mammal, and salted-out with ammonium sulfate to prepare a serum.
  • complete Freund's adjuvant or incomplete adjuvant or an equivalent thereof, such as Hunter's TiterMaxTM (
  • the antibody fragment of the present invention may be prepared, for example, by digesting the polyclonal antibody or monoclonal antibody of the present invention with a known protease by a conventional method, and then isolating and purifying by a conventional method.
  • the human ADAMTS-1 protein may be used as a diagnostic marker of an immunological state in a method for extracorporeally detecting the immunological state.
  • the extracorporeally detecting method of the present invention may be applied to a sample taken from a subject to be examined, to thereby detect an immunological state of an immune function of the subject, when the immune function is affected by various diseases, such as inflammation, cancer, cachexia, such as cancer cachexia or infectious disease-related cachexia, infectious disease, or leukemia. If the immune function of the subject is normal, an immunological state corresponding to the immune function can be detected.
  • the sample which may used in the present invention is not particularly limited, so long as it has a possibility of including the human ADAMTS-1 protein.
  • the sample may be a biological sample taken from a human, particularly a patient, for example, a humor, such as a tissue (e.g., cells) or an extract therefrom, blood, such as serum, and plasma, urine, or cerebrospinal fluid.
  • a sample used in a conventional clinical examination may be used in the present invention without limitation.
  • the sample is first brought into contact with the substance immunologically reactive to the human ADAMTS-1 protein. If the sample does not contain the human ADAMTS-1 protein, a reaction with the immunologically reactive substance does not occur. If the sample contains the human ADAMTS-1 protein, the immunologically reactive substance binds the human ADAMTS-1 protein, and a complex of the immunologically reactive substance and the human ADAMTS-1 protein is formed in an amount correlated with that of the human ADAMTS-1 protein present in the sample.
  • the complex may be easily detected by a known method, and therefore, an existence of the human ADAMTS-1 protein in the sample can be detected by detecting the existence of the complex, or an amount of the human ADAMTS-1 protein in the sample can be measured by measuring the amount of the complex.
  • the human ADAMTS-1 protein in a tissue or a cell may be measured, using a tissue section sample or a cell sample in a fluorescent antibody technique or an enzyme antibody technique.
  • the immunologically reactive substance capable of immunologically reacting the human ADAMTS-1 protein includes an anti-human ADAMTS-1 protein antiserum, an anti-human ADAMTS-1 protein polyclonal antibody, of an anti-human ADAMTS-1 protein monoclonal antibody, or a fragment thereof.
  • the immunologically reactive substance may be used singly or in combination thereof.
  • the fragment includes, for example, Fab, Fab', F(ab') 2 , or Fv.
  • the sample is brought into contact with the immunologically reactive substance capable of immunologically reacting the human ADAMTS-1 protein, and a complex of the human ADAMTS-1 protein and the immunologically reactive substance is formed. Then, the human ADAMTS-1 protein bound to the antibody is detected and the amount thereof is measured by an immunochemical method, to thereby find a level of the human ADAMTS-1 protein in the sample.
  • the immunochemical method principally may be, for example, any conventional immunoassay, for example, EIA, ELISA, RIA or the like.
  • the immunochemical methods are generally classified as follows:
  • a sample containing an unknown amount of antigens and a given amount of labeled antigens is competitively reacted with a given amount of antibodies, and then an activity of the labeled antigens bound to the antibodies or an activity of the labeled antigens not bound to the antibodies is measured.
  • An excess amount of antibodies immobilized on carriers is added and reacted to a sample containing an unknown amount of antigens (a first reaction). Then, a given excess amount of labeled antibodies is added and reacted therewith (a second reaction). An activity of the labeled antibodies on the carriers is measured. Alternatively, an activity of the labeled antibodies which are not on the carriers is measured.
  • the first reaction and the second reaction may be carried out at the same time, or sequentially.
  • a labeling agent is a radioactive isotope
  • a well counter or a scintillation counter may be used for measurement.
  • the labeling agent is an enzyme
  • an enzymatic activity can be measured by colorimetry or fluorimetry, after adding a substrate and allowing to stand.
  • the labeling agent is a fluorescent substance or an luminescent substance, a known method therefor may be used, respectively.
  • a western blotting method wherein electrophoresed proteins are transferred onto a filter such as a nitrocellulose membrane, and a target protein is detected with an antibody.
  • the western blotting method may also be used in the detection of the human ADAMTS-1 protein in the present invention.
  • the antibody used in the above methods can be labeled with an appropriate marker.
  • an appropriate marker examples are a radioactive isotope, an enzyme, a fluorescent substance, or a luminescent substance, by a known method of labeling antibodies.
  • the radioactive isotope may be, for example, 125 I, 131 I, 3 H, 14 C, or 35 S.
  • the enzyme used is stable and has a large specific activity.
  • examples of the enzyme are a glycosidase (such as, ⁇ -galactosidase, ⁇ -glucosidase, ⁇ -glucuronidase, ⁇ -fructosidase, ⁇ -galactosidase, ⁇ -glucosidase, or ⁇ -mannosidase), an amylase (such as, ⁇ -amylase, ⁇ -amylase, isoamylase, glucoamylase, or taka-amylase), a cellulase, or a carbohydrase such as lysozyme; a urease, or an amidase such as asparaginase; a choline esterase, such as acetylcholinesterase, a phosphatase, such as alkaline phosphatase, a sulfatase, an esterase such as lipase;
  • the fluorescent substance may be, for example, fluorescamine, or a fluorescence isothiocyanate, and the luminescent substance may be, for example, luminol, a luminol derivative, luciferin or lucigenin.
  • a signal from the above label may be detected by known methods.
  • the labeling agent can be bound to antibodies by any conventional method, such as a chloramin T method [Nature, 194 , 495-496, (1962)], a periodic acid method [Journal of Histochemistry and Cytochemistry, 22 , 1084-1091, (1974)], or a maleimide method [Journal of Biochemistry, 79 , 233-236, (1976)].
  • a chloramin T method [Nature, 194 , 495-496, (1962)]
  • a periodic acid method Journal of Histochemistry and Cytochemistry, 22 , 1084-1091, (1974)
  • a maleimide method Journal of Biochemistry, 79 , 233-236, (1976)
  • a sample is added to the first anti-human ADAMTS-1 protein antibodies immobilized on a carrier (such as an assay plate), and the anti-human ADAMTS-1 protein antibodies are bound to the human ADAMTS-1 proteins to form complexes.
  • a carrier such as an assay plate
  • the second anti-human ADAMTS-1 protein antibodies labeled with enzyme such as peroxidase
  • enzyme such as peroxidase
  • first antibody/human ADAMTS-1 protein/second antibody complexes To the resulting "first antibody/human ADAMTS-1 protein/second antibody” complexes, a substrate for the enzyme label (such as peroxidase) is added, and an absorbance or fluorescent strength of products of the enzymatic reaction is measured, whereby enzymatic activities of the enzyme labels attached to the "first antibody/human ADAMTS-1 protein/second antibody” complexes are measured.
  • a series of the above procedures is carried out in advance for a standard solution containing a known amount of the human ADAMTS-1 protein, and a standard curve based on the relationship between the human ADAMTS-1 protein and the absorbance or fluorescent strength is prepared. A comparison is made between the standard curve and absorbance or fluorescent strength for a sample containing an unknown amount of the human ADAMTS-1 proteins, and the amount of the human ADAMTS-1 proteins in the sample can be measured.
  • a sample is brought into contact with a carrier (such as an assay plate) to immobilize the human ADAMTS-1 proteins in the sample onto the carrier.
  • a carrier such as an assay plate
  • the anti-human ADAMTS-1 protein antibodies first antibodies
  • second antibodies anti-first antibody antibodies
  • enzyme such as peroxidase
  • a substrate for the enzyme label such as peroxidase
  • the absorbance or fluorescent strength of products of the enzymatic reaction is measured, whereby enzymatic activities of the enzyme labels attached to the "human ADAMTS-1 protein/first antibody/second antibody” complexes are measured.
  • a series of the above procedures is carried out in advance for a standard solution containing a known amount of the human ADAMTS-1 protein, and a standard curve based on the relationship between the human ADAMTS-1 protein and the absorbance or fluorescent strength is prepared.
  • a comparison is made between the standard curve and the absorbance or fluorescent strength for a sample containing an unknown amount of the human ADAMTS-1 proteins, and the amount of the human ADAMTS-1 proteins in the sample can be measured.
  • a sample is added to the first anti-human ADAMTS-1 protein antibodies immobilized on a carrier (such as a test tube), and the anti-human ADAMTS-1 protein antibodies are bound to the human ADAMTS-1 proteins to form complexes.
  • a carrier such as a test tube
  • the second anti-human ADAMTS-1 protein antibodies labeled with radioactive isotope such as 125 I
  • radioactive isotope such as 125 I
  • a series of the above procedures is carried out in advance for a standard solution containing a known amount of the human ADAMTS-1 protein, and a standard curve based on the relationship between the human ADAMTS-1 protein and the radioactivity is prepared.
  • a comparison is made between the standard curve and the radioactivity for a sample containing an unknown amount of the human ADAMTS-1 proteins, and the amount of the human ADAMTS-1 proteins in the sample can be measured.
  • a sample is brought into contact with a carrier (such as a test tube) to immobilize the human ADAMTS-1 proteins in the sample onto the carrier.
  • a carrier such as a test tube
  • the anti-human ADAMTS-1 protein antibodies first antibodies
  • second antibodies labeled with radioactive isotope (such as 125 I)
  • radioactive isotope such as 125 I
  • a series of the above procedures is carried out in advance for a standard solution containing a known amount of the human ADAMTS-1 protein, and a standard curve based on the relationship between the human ADAMTS-1 protein and the radioactivity is prepared.
  • a comparison is made between the standard curve and the radioactivity for a sample containing an unknown amount of the human ADAMTS-1 proteins, and the amount of the human ADAMTS-1 proteins in the sample can be measured.
  • the sample is reacted with a polynucleotide containing a base sequence complementary to that of the mRNA of the human ADAMTS-1 protein, and the resulting complex of the mRNA of the human ADAMTS-1 protein and the polynucleotide is detected, or the amount of the complex is measured to thereby analyze the mRNA of the human ADAMTS-1 protein.
  • the polynucleotide contains a sequence complementary or substantially complementary to that of a part of the mRNA transcribed from a selected gene (DNA), and thus forms a double strand with the mRNA transcribed from the target gene. It is believed that any polynucleotide sufficiently complementary to form a stable complex with a target mRNA can be used.
  • the polynucleotide able to be used in the present invention may be complementary to substantially any region in a target mRNA.
  • the polynucleotide can be used as a DNA probe for detecting an increase or a decrease of expression of the mRNA specific to the human ADAMTS-1 protein gene. That is, the polynucleotide is specifically attached to the mRNA of the target human ADAMTS-1 protein, and forms a molecular hybrid, whereby a degree of expression of the human ADAMTS-1 protein in cells can be detected.
  • the polynucleotide able to be used in the present invention may be prepared by appropriately selecting a base sequence complementary to a specific base sequence of the mRNA of the target human ADAMTS-1 protein, and using a known DNA synthesizer, a known PCR apparatus, a gene cloning or the like.
  • Various length polynucleotides may be used, but the polynucleotide preferably has 10 or more bases, more preferably 17 or more bases.
  • the polynucleotide may be a non-modified polynucleotide or a polynucleotide analogue.
  • An appropriate analogue may be, for example, an ethyl or methyl phosphate analogue, or a phosphorothioated polydeoxynucleotide [Nucleic Acids Res., 14 , 9081-9093, (1986); J. Am. Chem.
  • RNA-DNA analogue for example, a conjugated RNA-DNA analogue, i.e., chimera polynucleotide [FEBS Lett., 215 , 327-330, (1987)], may be used.
  • the selected polynucleotide may be of any kind, for example, may have an electrical charge or no electrical charge.
  • the polynucleotide may be labeled with a known labeling agent, such as a radioactive isotope, or a fluorescent substance by a conventional method, so as to carry out the above experiment in vitro or in vivo.
  • the radioactive isotope may be, for example, 125 I, 131 I, 3 H, 14 C, 32 P, or 35 S. Of these radioactive isotopes, it is preferable to label the polynucleotide with 32 P by a random primer method [Anal. Biochem., 132, 6-13, (1983)].
  • a fluorescent coloring agent forming a derivative may be used as a labeling agent, as this enables an easy handling with a low risk factor.
  • the fluorescent coloring agent any coloring agents capable of binding the polynucleotide may be used.
  • fluorescein, rhodamin, Texas red, 4-fluoro-7-nitrobenzofurazane (NBD), coumarin, fluorescamine, succinyl fluorescein, or dansyl may be preferably used.
  • An amount of an mRNA of the human ADAMTS-1 protein may be measured by a northern blotting method, using cDNA of the human ADAMTS-1 protein as follows: an mRNA is extracted and isolated from any somatic cell or tissue, then the isolated mRNA is electrophoresed on an agarose gel and transferred onto a nitro cellulose or nylon membrane, and then reacted with a labeled human ADAMTS-1 protein cDNA probe to measure an amount of the mRNA of the human ADAMTS-1 protein.
  • the human ADAMTS-1 protein cDNA probe used is a DNA complementary to the human ADAMTS-1 protein mRNA, and has preferably 17 or more bases.
  • the agent for analyzing an immunological state contains, as a main ingredient, the immunologically reactive substance capable of immunologically reacting the human ADAMTS-1 protein.
  • the immunologically reactive substance capable of immunologically reacting the human ADAMTS-1 protein may be, for example, an anti-human ADAMTS-1 protein antiserum, an anti-human ADAMTS-1 protein polyclonal antibody, or an anti-human ADAMTS-1 protein monoclonal antibody, of a fragment of the antibodies.
  • the agent for analyzing an immunological state according to the present invention may contain, as a main ingredient, the polynucleotide containing the base sequence complementary to that of an mRNA of the human ADAMTS-1 protein, instead of the immunologically reactive substance.
  • the human ADAMTS-1 protein per se or an mRNA of the human ADAMTS-1 protein in a sample can be analyzed according to the above methods using the agent for analyzing an immunological state according to the present invention, and the immunological state of a subject to be examined, wherein the immune function is affected by various diseases, can be judged from the result.
  • Example 1 Isolation of the human ADAMTS-1 cDNA and determination of the base sequence thereof
  • a DNA [hereinafter referred to as a "forward primer (1)"] having the base sequence (i.e., the base sequence of SEQ ID NO: 4: AGAACCTGTG GTGGTGGAGT TCAATACACA) corresponding to an amino acid sequence (i.e., the amino acid sequence of SEQ ID NO: 3: Arg Thr Cys Gly Gly Gly Val Gln Tyr Thr) contained in the first thrombospondin (TSP) domain from the N-terminus among three TSP domains of the mouse ADAMTS-1 protein [J. Biol.
  • the base sequence i.e., the base sequence of SEQ ID NO: 5: CCTCTTAACT GCACTGTGTC AGTGTGCAAA AG
  • the base sequence in the vicinal regions i.e., the regions upstream and downstream of the C-terminus
  • a PCR method was performed at an annealing temperature lower than that used in a standard PCR method.
  • the PCR reaction was carried out by repeating a cycle composed of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, and DNA synthesis at 72°C for 2 minutes, 40 times, i.e., 40 cycles.
  • a sample (5 ⁇ l) was taken from the resulting reaction mixture, and electrophoresed on 1% agarose gel. As shown in Fig. 1, a single DNA band of 1.2 Kb was observed. The rest of the reaction mixture was electrophoresed, and the DNA fragment of 1.2 Kb (hereinafter sometimes referred to as a "Flag. 1 DNA fragment”) was recovered from a low-melting-point agarose gel. Then, the Flag. 1 DNA fragment was cloned in a pCRTM 2.1 vector (Invitrogen Corp., San Diego, CA, USA).
  • a part (303 bp) of the base sequence of the cloned Flag. 1 DNA fragment was determined by an automatic DNA sequencer (DSQ1000; Shimadzu Corp., Kyoto, Japan).
  • a homology search between the partial base sequence of the cloned Flag. 1 DNA fragment and the base sequence of the mouse ADAMTS-1 was conducted to find that a homology in the base sequences was 77.4%.
  • the partial base sequence of the Flag. 1 DNA fragment and a partial base sequence of the mouse ADAMTS-1 gene having a homology therewith are shown in Fig. 2.
  • the symbol ":" in Fig. 2 means that a base in the Flag. 1 DNA fragment is identical to a corresponding base in the mouse ADAMTS-1 gene.
  • a dot hybridization [Biochemistry, 16 , 4743-4749 (1977)] was conducted to find that a mouse ADAMTS-1 cDNA labeled with 32 P by a random primed DNA-labeling kit (Boehringer Manmheim GmbH, Germany) was hybridized with the Flag. 1 DNA fragment.
  • the results are shown in Fig. 3.
  • a pCRTM2.1 vector as a control was not hybridized with 32 P-labeled mouse ADAMTS-1 cDNA, whereas the mouse ADAMTS-1 cDNA and the Flag. 1 DNA fragment were hybridized with 32 P-labeled mouse ADAMTS-1 cDNA.
  • the results of the homology search and dot hybridization mean that the Flag. 1 DNA fragment is a part of the human ADAMTS-1.
  • a R apid a mplification of c DNA e nds (RACE) method using a Marathon cDNA Amplification kit was performed as follows. That is, as back primers for the base sequence of the Flag. 1 DNA fragment, a DNA primer (hereinafter sometimes referred to as a "GSP-1 primer") having the base sequence (i.e., the base sequence of SEQ ID NO: 6: CCTCTTAACT GCACTGTGTC AGT) complementary to the base sequence of the 3'-end region of the Flag.
  • GSP-1 primer a DNA primer having the base sequence (i.e., the base sequence of SEQ ID NO: 6: CCTCTTAACT GCACTGTGTC AGT) complementary to the base sequence of the 3'-end region of the Flag.
  • GSP-2 primer a DNA primer having the base sequence (i.e., the base sequence of SEQ ID NO: 7: CAGGCCCACT CCCAAAGGAA GCTT) complementary to the base sequence of the 5'-end region of the Flag. 1 DNA fragment were chemically synthesized.
  • forward primers an AP1 primer and an AP2 primer attached to the above kit were used.
  • the AP1 primer had the base sequence of SEQ ID NO: 8: and the AP2 primer had the base sequence of SEQ ID NO: 9:
  • PCR reaction was carried out by repeating a cycle composed of a step at 94°C for 30 seconds and a step at 68°C for 4 minutes, 35 times, i.e., 35 cycles.
  • the resulting reaction mixture was diluted to 50-fold with 10 mM Tricine-EDTA buffer (Clontech Lab. Inc., Palo Alto, CA, USA).
  • PCR reaction was carried out by repeating a cycle composed of a step at 94°C for 30 seconds and a step at 68°C for 4 minutes 20 times, i.e., 20 cycles.
  • Flag. 2 DNA fragment was cloned in a pCRTM 2.1 vector by a conventional method, and the full-length base sequence of the Flag. 2 DNA fragment determined by a Dye Terminator Cycle Sequencing method (Perkin Elmer Japan, Urayasu, Japan).
  • the full-length base sequence of the Flag. 1 DNA fragment was determined by the Dye Terminator Cycle Sequencing method (Perkin Elmer Japan, Urayasu, Japan). From the obtained base sequences of the Flag. 1 DNA fragment and the Flag. 2 DNA fragment, the full-length base sequence of the human ADAMTS-1 cDNA was determined. The full-length base sequence (2184 bp including a stop codon) is shown in SEQ ID NO: 2 and the amino acid sequence (727 amino acid residues) of the human ADAMTS-1 protein deduced from the above base sequence is shown in SEQ ID NO: 1. The partial base sequence of the Flag. 1 DNA fragment as shown in Fig.
  • SEQ ID NO: 2 contains some bases not identical to the full-length base sequence of the human ADAMTS-1 cDNA (SEQ ID NO: 2). However, the partial base sequence as shown in Fig. 2 was an interim sequence obtained in the process of determining the base sequence.
  • the base sequence of SEQ ID NO: 2 is a correct base sequence of the human ADAMTS-1 cDNA which has been finally determined.
  • the human ADAMTS-1 protein is cysteine-rich, and contains many basic amino acids such as lysine and arginine in the C-terminal region, and two N-glycosylation sites (the 307th to 309th amino acids and 524th to 526th amino acids).
  • Figs. 5 to 9 The homology between the base sequences of the human ADAMTS-1 gene and the mouse ADAMTS-1 gene is shown in Figs. 5 to 9, and the homology in the amino acid sequences deduced from the base sequences is shown in Figs. 10 to 12.
  • Figs. 5 to 9 the symbol "*" means that a base of the human ADAMTS-1 gene is identical to the corresponding base of the mouse ADAMTS-1 gene.
  • Figs. 10 to 12 the symbol “*” means that an amino acid residue of the human ADAMTS-1 protein is identical to the corresponding amino acid residue of the mouse ADAMTS-1 protein.
  • MMP domain means a matrix metalloproteinase domain; the line between the 11th and 12th amino acids indicates the starting site of the matrix metalloproteinase domain;
  • DI domain means the disintegrin domain; the line between the 234th and 235th amino acids indicates the starting site of the disintegrin domain;
  • TSP domain means the thrombospondin domain; and amino acid sequences in boxes (three occurrences) mean the thrombospondin domain.
  • ADAMTS-1 is the protein of which, between mouse and human, the sequences have been preserved.
  • a forward primer (2) having the base sequence of SEQ ID NO: 10: and a back primer (2) having the base sequence of SEQ ID NO: 11: were chemically synthesized.
  • PCR reaction was carried out by repeating a cycle composed of a step at 94°C for 1 minute, a step at 55°C for 45 seconds, and a step at 72°C for 2 seconds 40 times, i.e., 40 cycles.
  • a sample (5 ⁇ l) was taken from the resulting reaction mixture, and electrophoresed on 1% agarose gel. As shown in Fig. 13, a single DNA band of about 2.2 Kb was obtained.
  • the DNA fragment of about 2.2 Kb was cloned in the pCRTM 2.1 vector by a conventional method, and a large quantity of the plasmids produced [Nucleic Acids Res., 9 , 2989-2998 (1981)].
  • the resulting plasmids prepared on a large scale were treated with restriction enzymes, SmaI (Takarashuzo, Kyoto, Japan) and NotI (Takarashuzo, Kyoto, Japan) to obtain a DNA fragment of about 2.2 Kb.
  • the DNA fragment of about 2.2 Kb was cloned in a SmaI-NotI site of an expression vector for E. coli pGEX-5X-1 [Infect Immun., 58 , 3909-3913 (1990)] (Pharmacia Biotech, Uppsala, Sweden).
  • the resulting expression plasmid was named pG/ADAMTS-1.
  • the structure of the plasmid pG/ADAMTS-1 is schematically shown in Fig. 14.
  • GST glutathione-S-transferase
  • Ori means a replication origin
  • Amp R means an ampicillin resistance gene
  • laq I q means a laq repressor.
  • the plasmid pG/ADAMTS-1 was introduced into an E. coli BL-21 strain having a low protease activity (Pharmacia Biotech, Uppsala, Sweden) by a conventional method [Proc. Natl. Acad. Sci. USA, 69 , 2110-2114 (1972)]. E. coli clones containing the plasmid were isolated as ampicillin resistance strains.
  • clone #1 Five ampicillin resistance strains (hereinafter referred to as "clone #1" to "clone #5") randomly selected from the strains were used to inoculate 2 ml of 2xYT medium (prepared by dissolving 16 g of trypton, 10 g of yeast extract, and 5g of NaCl in 1 liter of distilled water; pH 7.2), and cultured overnight at 37°C. Then, a set of two test tubes containing 1800 ⁇ l of an LB culture medium containing ampicillin (100 ⁇ g/ml) was prepared for each clone. To each test tube, 200 ⁇ l of the overnight culture was poured.
  • 2xYT medium prepared by dissolving 16 g of trypton, 10 g of yeast extract, and 5g of NaCl in 1 liter of distilled water; pH 7.2
  • IPTG isopropyl- ⁇ -D-thio-galactopyranoside
  • Microorganisms were harvested by centrifugation (14000 rpm, 1 minute) from 1 ml of the culture, using a microcentrifuging apparatus, then suspended in 100 ⁇ l of a phosphate-buffered solution (140mM NaCl, 2.7mM KCl, 10mM Na 2 HPO 4 , 1.8mM KH 2 PO 4 , pH 7.2; hereinafter referred to as a PBS) and thereafter dissolved in 100 ⁇ l of a 2 ⁇ sample buffer (0.25M Tris-HCl, 2% SDS, 3% glycerol, 10% ⁇ -mercaptoethanol, 0.01% bromophenol blue; pH 6.8).
  • a phosphate-buffered solution 140mM NaCl, 2.7mM KCl, 10mM Na 2 HPO 4 , 1.8mM KH 2 PO 4 , pH 7.2; hereinafter referred to as a PBS
  • a 2 ⁇ sample buffer (0.25M Tri
  • the resulting solution (10 ⁇ l) was subjected to an SDS-polyacrylamide gel electrophoresis (hereinafter sometimes referred to as an "SDS-PAGE"), and an expression induction of the desired protein was confirmed by a Coomassie staining method.
  • SDS-PAGE SDS-polyacrylamide gel electrophoresis
  • clone #2 exhibited the highest expression, and thus was used in the following Examples.
  • E. coli was harvested by centrifugation (3000 rpm, 30 minutes) from the culture, and then suspended in 8 ml of PBS. To the suspension, 1 ml of 0.5M EDTA solution and 1 ml of 25 mg/ml lysozyme solution were added, and the whole was allowed to stand in ice for 30 minutes. After 110 ⁇ l of Triton X-100 was added, the microorganisms were disrupted on ice by a sonicator (TAITEC, Koshigaya, Japan).
  • TITEC Triton X-100
  • the disruption liquid was centrifuged (8000 rpm, 4°C, 10 minutes), then the resulting precipitate suspended in 30 ml of PBS containing 1.0% Triton X-100, and thereafter centrifuged (8000 rpm, 4°C, 10 minutes).
  • the resulting precipitate was suspended in 2 ml of a 10 mM EDTA solution, and then, 50 ml of a 50 mM Tris-HCl buffer (pH 8.5) containing 8 M urea and 1% mercaptoethanol was added. After a thorough admixing, the mixture was centrifuged (15000 rpm, 4°C, 5 minutes). The resulting supernatant was dialyzed against 5 liters of a 10 mM Tris-HCl buffer (pH 8.5) at 4°C.
  • the glutathione Sepharose 4B was washed with 50 ml of PBS, and then eluted with 8 ml of 10 mM glutathione solution [Nucleic Acids Res., 9 , 2989-2998 (1981)]. Fractions exhibiting a high GST activity detected by a GST detecting kit (Pharmacia Biotech, Uppsala, Sweden) were pooled.
  • a GST-human ADAMTS-1 fusion protein was confirmed from the molecular weight.
  • the desired protein (about 1 ⁇ g) was extracted and purified from 100 ml of E. coli culture.
  • the resulting fusion protein contains a site which may be broken with a Factor Xa or the like, between the GST and the human ADAMTS-1 protein, and therefore, the human ADAMTS-1 protein can be obtained by digesting the fusion protein with the proteinase.
  • the human ADAMTS-1 protein may be used as an antigen to prepare an antibody.
  • Example 3 Examination of activities of GST-human ADAMTS-1 fusion protein on influencing hematopoietic functions
  • Example 2 To examine the activities of the GST-human ADAMTS-1 fusion protein on influencing hematopoietic functions, a large-scale preparation of the GST-human ADAMTS-1 fusion protein was carried out in accordance with the process disclosed in Example 2 (3), and about 30 ⁇ g of the desired protein was obtained from 3 liters of E. coli culture.
  • the functions thought to influence the number of blood cells by a single dosage of the GST-human ADAMTS-1 fusion protein to a tail vein of a mouse were examined, as the activities influencing hematopoietic functions.
  • the examining system can be conducted with a small amount of a protein to be examined, and enables a quick elucidation of a biological activity.
  • a GST protein extracted and purified by the process disclosed in Example 2(3) from E. coli transformed with a vector pGEX-5X-1 was used.
  • the GST-human ADAMTS-1 fusion protein (1 ⁇ g) was administered to eight C57BL/6N mice (Charlese river Japan, Yokohama, Japan) (male, 7 weeks old) at a tail vein. The numbers of leukocytes, erythrocytes, and platelets were counted 3 hours and 24 hours after the administration.
  • the GST protein (1 ⁇ g) was administered to eight C57BL/6N mice (Charlese river Japan, Yokohama, Japan) (male, 7 weeks old) at a tail vein. The numbers of leukocytes, erythrocytes, and platelets were counted 3 hours and 24 hours after the administration.
  • Fig. 17 The results are shown in Fig. 17. It is apparent from Fig. 17 that the number of leukocytes and platelets is significantly decreased, and the number of erythrocytes is significantly increased in the mice to which the GST-human ADAMTS-1 fusion protein was administered, in comparison with the control tests.
  • hematopoietic functions can be controlled, for example, the number of leukocytes and platelets can be decreased, and at the same time, the number of erythrocytes can be increased.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (10)

  1. Protéine contenant la séquence d'amino-acides de la SEQ ID N° 1.
  2. Gène contenant la séquence de bases codant pour ladite protéine suivant la revendication 1.
  3. Vecteur contenant ledit gène suivant la revendication 2.
  4. Transformant transformé par ledit vecteur suivant la revendication 3.
  5. Composition pharmaceutique comprenant une protéine contenant la séquence d'amino-acides de la SEQ ID N 1 et un support acceptable du point de vue pharmaceutique ou vétérinaire.
  6. Utilisation
    (1) d'une protéine contenant la séquence d'amino-acides de la SEQ ID N° 1, ou
    (2) une variante fonctionnellement équivalente à ladite protéine contenant ladite séquence d'amino-acides de la SEQ ID N° 1, ladite variante ayant une séquence d'amino-acides dans laquelle un ou plusieurs amino-acides sont éliminés par délétion de, remplacés dans, ou insérés dans la séquence d'amino-acides, de la SEQ ID N° 1, et présentant des activités d'une protéine ADAMTS-1 humaine, dans la production d'un médicament destiné au traitement d'une maladie inflammatoire, de l'hypervolémie vraie, de l'infarctus du myocarde, d'une infection cérébrale, d'une déficience d'organes multiples ou de l'anémie.
  7. Additif alimentaire comprenant une protéine contenant la séquence d'amino-acides de la SEQ ID N° 1.
  8. Substance immunologiquement réactive caractérisée par sa réactivité spécifique avec ladite protéine suivant la revendication 1.
  9. Méthode d'analyse immunologique d'une protéine ADAMTS-1 humaine contenant la séquence d'amino-acides de la SEQ ID N° 1, dans laquelle un échantillon est mis en contact avec une substance immunologiquement réactive qui est réactive spécifiquement avec ladite protéine ADAMTS-1 humaine, et un complexe de ladite protéine ADAMTS-1 humaine et de ladite substance immunologiquement réactive est détecté.
  10. Méthode d'analyse d'un ARNm d'une protéine ADAMTS-1 humaine contenant la séquence d'amino-acides de la SEQ ID N° 1, dans laquelle un échantillon est mis en contact avec un polynucléotide contenant une séquence de bases complémentaire de celle dudit ARNm de ladite protéine ADAMTS-1 humaine, et un complexe dudit ARNm de ladite protéine ADAMTS-1 humaine et dudit polynucléotide est détecté.
EP98923100A 1997-06-03 1998-06-03 Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine Expired - Lifetime EP1004674B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16042297 1997-06-03
JP16042297 1997-06-03
PCT/JP1998/002449 WO1998055643A1 (fr) 1997-06-03 1998-06-03 Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine

Publications (3)

Publication Number Publication Date
EP1004674A1 EP1004674A1 (fr) 2000-05-31
EP1004674A4 EP1004674A4 (fr) 2002-01-09
EP1004674B1 true EP1004674B1 (fr) 2004-03-10

Family

ID=15714592

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923100A Expired - Lifetime EP1004674B1 (fr) 1997-06-03 1998-06-03 Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine

Country Status (4)

Country Link
US (3) US6565858B2 (fr)
EP (1) EP1004674B1 (fr)
DE (1) DE69822307T2 (fr)
WO (1) WO1998055643A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220557B2 (en) 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
AU8901198A (en) * 1997-08-06 1999-03-01 Millennium Pharmaceuticals, Inc. Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
JP2002501077A (ja) * 1998-01-23 2002-01-15 ベス イスラエル デアコネス メディカル センター Ｍｅｔｈ１およびｍｅｔｈ２のポリヌクレオチドおよびポリペプチド
JP2002516118A (ja) 1998-05-29 2002-06-04 ウイスコンシン アラムニ リサーチ ファンデーション 細胞遊走調節のための物質および方法
AU3622600A (en) * 1999-03-08 2000-09-28 Neurocrine Biosciences, Inc. Metalloproteinases and methods of use therefor
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
WO2001088155A2 (fr) * 2000-05-15 2001-11-22 Millennium Pharmaceuticals, Inc. 33428, un nouveau membre de la famille des metalloproteases humaines et ses utilisations
EP1282823B1 (fr) 2000-05-17 2014-05-07 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Enzymes protéolytiques pour le diagnostic de maladies rénales
SE0002973D0 (sv) * 2000-08-22 2000-08-22 Astrazeneca Ab Method
WO2002033087A2 (fr) * 2000-10-17 2002-04-25 Curagen Corporation Proteines et acides nucleiques codant les memes
WO2002042439A2 (fr) * 2000-10-27 2002-05-30 Genetics Institute, Llc Molecules d'aggrecanase
US20060063152A1 (en) 2000-12-22 2006-03-23 Osamu Ohara Novel gene and protein encoded by the gene
AU2002336367A1 (en) * 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US7696307B2 (en) * 2004-04-12 2010-04-13 The Trustees Of The University Of Pennsylvania Function and regulation of ADAMTS-1
WO2007147497A2 (fr) * 2006-06-17 2007-12-27 Bayer Healthcare Ag Utilisation d'un domaine du type désintégrine et métalloprotéinase à motif de thrombospondine de type 1 (adamts1) comme cible thérapeutique et diagnostique
US20110301228A1 (en) * 2009-02-11 2011-12-08 The University Of North Carolina At Chapel Hill Gene therapy vector for treatment of steroid glaucoma
CN103492112B (zh) * 2012-04-16 2016-08-17 株式会社谷黑组 焊接装置、焊接方法以及所制造的基板及电子部件
WO2014078713A1 (fr) * 2012-11-15 2014-05-22 Feldman Brian Jay Modulation de la distribution de muscle et d'adipocytes et de leur devenir
KR102486046B1 (ko) * 2020-12-14 2023-01-11 주식회사 뉴온바이오 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
KR102486047B1 (ko) * 2020-12-14 2023-01-11 주식회사 뉴온바이오 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166065A1 (en) * 1997-04-24 2003-09-04 Human Genome Sciences, Inc. Novel integrin ligand ITGL-TSP
EP0874050A3 (fr) 1997-04-24 2002-06-05 Smithkline Beecham Corporation Ligand d'integrin ITGL-TSP
AU8901198A (en) * 1997-08-06 1999-03-01 Millennium Pharmaceuticals, Inc. Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor

Also Published As

Publication number Publication date
EP1004674A4 (fr) 2002-01-09
US20020119167A1 (en) 2002-08-29
DE69822307D1 (de) 2004-04-15
WO1998055643A1 (fr) 1998-12-10
EP1004674A1 (fr) 2000-05-31
US6565858B2 (en) 2003-05-20
DE69822307T2 (de) 2005-02-17
US20030032168A1 (en) 2003-02-13
US20030022352A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
EP1004674B1 (fr) Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine
US7285275B2 (en) Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor
JP3220752B2 (ja) Ｍｔｓ−１遺伝子により転移性癌の診断
EP1092772A1 (fr) Anticorps contre une sous-unite de phosphatase lar
JP2001510987A (ja) 哺乳動物のＣＤ９７αサブユニットを含む炎症および脈管形成を阻害するための方法および組成物
JP2002515724A (ja) ヒト血清中に見出されたジペプチジルペプチダーゼｉｖ（ｃｄ２６）の新規形態、その抗体および利用法
JPH10179170A (ja) ヒト軟骨ｇｐ−３９様遺伝子
JP2930713B2 (ja) タンパク質ホルモン形成の抑制用の組成物およびその使用法
US5484703A (en) Assay using recombinant histidyl-tRNA synthetase
EP1544293B1 (fr) Anticorps dirige contre le facteur von willebrand clivant specifiquement une enzyme et methode d'essai
JPH11507823A (ja) 新規なヒト視床下部由来セルピン
JP3527733B2 (ja) Ｍｔｓ−１遺伝子による転移性の癌の診断
JP2004513066A (ja) アンジオシジン：ｃｙｓ−ｓｅｒ−ｖａｌ−ｔｈｒ−ｃｙｓ−ｇｌｙ特異的腫瘍細胞付着受容体
WO1998005786A2 (fr) Enzymes de transformation afc1 et rce1: caax isoprenyles
EP1187853B1 (fr) Nouvelles utilisations diagnostiques d'anticorps diriges contre l'acetylcholinesterase ou ses peptides c-terminaux
JP3741867B2 (ja) ヒトａｄａｍｔｓ−１タンパク質、それをコードする遺伝子、医薬組成物、及びヒトａｄａｍｔｓ−１タンパク質の免疫学的分析方法
JPH10512154A (ja) 膵臓で発現する新規なケモカイン
JP2004222722A (ja) ヒトａｄａｍｔｓ−１タンパク質、それをコードする遺伝子、医薬組成物、及びヒトａｄａｍｔｓ−１タンパク質の免疫学的分析方法
JP2003000249A (ja) クローディンによるＭＴ−ＭＭＰｓを介したｐｒｏＭＭＰ−２活性化
EP1132092A1 (fr) Inhibiteur et potentialisateur du facteur de couplage cf6 et utilisation correspondante
JP4491536B2 (ja) 新規硫酸転移酵素及びその遺伝子
JPH10501966A (ja) ヒトｄｎａトポイソメラーゼｉ−アルファ
JPH08143599A (ja) ヒト由来のチトクロムｐ４５０１ａ１を認識する抗体
MXPA97000151A (en) Elastase iv hum

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/57 A, 7C 12P 21/02 B, 7C 12N 15/12 B, 7C 12N 1/21 B, 7A 61K 38/43 B, 7A 61K 38/48 B, 7A 61K 38/16 B, 7G 01N 33/53 B, 7A 23L 1/305 B, 7C 07K 16/40 B

A4 Supplementary search report drawn up and despatched

Effective date: 20011127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20020205

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KUREHA CHEMICAL INDUSTRY CO., LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

REF Corresponds to:

Ref document number: 69822307

Country of ref document: DE

Date of ref document: 20040415

Kind code of ref document: P

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20041213

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100709

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100602

Year of fee payment: 13

Ref country code: DE

Payment date: 20100526

Year of fee payment: 13

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110603

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120229

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69822307

Country of ref document: DE

Effective date: 20120103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120103

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110603